|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/14 | |
| C12N 9/10 | |||
| C12P 21/00 | |||
| C12Q 1/48 | |||
| C07K 16/00 |
| (11) | Number of the document | 2991666 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14792116.7 |
| Date of filing the European patent application | 2014-05-01 | |
| (97) | Date of publication of the European application | 2016-03-09 |
| (45) | Date of publication and mention of the grant of the patent | 2020-03-25 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/036413 |
| Date | 2014-05-01 |
| (87) | Number | WO 2014/179601 |
| Date | 2014-11-06 |
| (30) | Number | Date | Country code |
| 201361818563 P | 2013-05-02 | US |
| (72) |
BHATNAGAR, Naveen, US
MECCARIELLO, Robin, US
LANSING, Jonathan, C., US
ORTIZ, Daniel, US
SARVAIYA, Hetal, US
WASHBURN, Nathaniel, US
|
| (73) |
Momenta Pharmaceuticals, Inc.,
301 Binney Street, Cambridge, MA 02142,
US
|
| (54) | SIALYLATED GLYCOPROTEINS |
| SIALYLATED GLYCOPROTEINS |